DeepMed Research

Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery

Phase 3

Completed

Conditions: Cataract

Interventions: Drug: Mapracorat
Drug: Vehicle

First Posted Date: 2010-10-28

Last Posted Date: 2020-09-03

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 311

Registration Number: NCT01230125

Locations: 🇺🇸
Bausch & Lomb, Incorporated, Rochester, New York, United States

Three Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction

Phase 4

Completed

Conditions: Cataract

Interventions: Device: ReSTOR 3.0
Device: Crystalens AO
Device: AMO Tecnis Multifocal

First Posted Date: 2010-10-21

Last Posted Date: 2013-01-18

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 93

Registration Number: NCT01225952

Locations: 🇵🇭
Asian Eye Institute, Makati City, Philippines

Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Intraocular Pressure

Interventions: Drug: BOL-303259-X
Drug: Latanoprost

First Posted Date: 2010-10-19

Last Posted Date: 2018-07-24

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 413

Registration Number: NCT01223378

Locations: 🇺🇸
Bausch & Lomb, Inc, Rochester, New York, United States

Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber

Phase 1

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: bepotastine besilate nasal product - medium dose
Drug: bepotastine besilate nasal product - high dose
Drug: placebo comparator nasal product
Drug: bepotastine besilate nasal product - low dose

First Posted Date: 2010-10-18

Last Posted Date: 2020-10-05

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 89

Registration Number: NCT01222299

Locations: 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States

A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease

Phase 3

Completed

Conditions: Dry Eye Syndrome

Interventions: Drug: Bromfenac Ophthalmic Solution A
Drug: Bromfenac Ophthalmic Solution B
Drug: Placebo Comparator

First Posted Date: 2010-09-30

Last Posted Date: 2020-09-04

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 840

Registration Number: NCT01212471

Locations: 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States

A Study to Evaluate the Product Performance of a Daily Disposable Contact Lens

Not Applicable

Completed

Conditions: Myopia
Contact Lenses

Interventions: Device: Bausch & Lomb new daily disposable
Device: Johnson & Johnson Acuvue Moist

First Posted Date: 2010-08-31

Last Posted Date: 2014-01-03

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 102

Registration Number: NCT01192126

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle

Phase 3

Completed

Conditions: Bacterial Conjunctivitis

Interventions: Drug: Vehicle
Drug: Besivance

First Posted Date: 2010-08-05

Last Posted Date: 2013-05-01

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 518

Registration Number: NCT01175590

Locations: 🇺🇸
Bausch & Lomb, Inc., Rochester, New York, United States

Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients

Phase 2

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: bepotastine besilate ophthalmic solution
Drug: placebo comparator ophthalmic solution

First Posted Date: 2010-08-04

Last Posted Date: 2020-09-14

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 245

Registration Number: NCT01174823

Locations: 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States

Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

Phase 2

Completed

Conditions: Dry Eye Syndrome

Interventions: Drug: 2% BOL-303242-X ophthalmic suspension
Drug: 0.3% BOL-303242-X ophthalmic suspension
Drug: 1% BOL-303242-X ophthalmic suspension
Drug: 2% BOL-303242-X ophthalmic suspension AM
Drug: 2% BOL-303242-X ophthalmic suspension PM

First Posted Date: 2010-07-16

Last Posted Date: 2020-09-25

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 356

Registration Number: NCT01163643

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers

Phase 3

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: KetoNaph
Drug: Vehicle

First Posted Date: 2010-07-09

Last Posted Date: 2020-10-05

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 534

Registration Number: NCT01159015

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy